Pediatric Brain Tumors Market Report 2026

Pediatric Brain Tumors Market Overview

• Pediatric Brain Tumors market size has reached to $1.4 billion in 2025 • Expected to grow to $1.93 billion in 2030 at a compound annual growth rate (CAGR) of 6.6% • Growth Driver: Impact Of Personalized Medicine On The Market Growth • Market Trend: FDA Grants Accelerated Approval For Targeted Therapy In Pediatric Low-Grade Glioma Treatment • North America was the largest region in 2025.

What Is Covered Under Pediatric Brain Tumors Market?

Pediatric brain tumors are abnormal growths of cells in the brain or central nervous system (CNS) of children. These tumors can be benign (non-cancerous) or malignant (cancerous) and can originate in different parts of the brain or spinal cord. The goal of treatment is to shrink or remove the tumor, relieve symptoms, and preserve cognitive and motor functions, ensuring the child's long-term health and development. The main types of pediatric brain tumors are gliomas, mixed neuronal-glial tumors, embryonal tumors, choroid plexus papilloma or carcinoma, and tumors arising from non-neuroepithelial tissue and meningeal tumors. Gliomas are the most common pediatric brain tumors, arising from glial cells and including subtypes varying in severity and requiring aggressive treatment due to their infiltrative growth and recurrence potential. It is cured by various treatment types, such as surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, with several diagnostic methods, including imaging techniques, biopsy, neurological exams, and lumbar puncture. It is found in various age groups, including infants, toddlers, children, and adolescents, and used in various applications such as hospitals and clinics, medical research centers, academic institutes, and others.

What Is The Pediatric Brain Tumors Market Growth Forecast?

The pediatric brain tumors market size is expected to see strong growth in the next few years. It will grow to $1.93 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to growing incidence of pediatric brain tumors, increasing adoption of precision medicine, rising integration of ai and digital imaging in diagnostics, growing focus on personalized treatment plans, increasing funding for pediatric neuro-oncology research. Major trends in the forecast period include increasing adoption of precision medicine for pediatric brain tumors, rising integration of digital imaging and ai-based diagnostics, growing use of targeted therapies and immunotherapies, increasing focus on minimally invasive surgical techniques, rising investment in pediatric neuro-oncology research.

Global Pediatric Brain Tumors Market Segmentation

1) By Type: Gliomas, Mixed Neuronal-Glial Tumors, Embryonal Tumors, Choroid Plexus Papilloma Or Carcinoma, Tumors Arising From Non-Neuroepithelial Tissue, Meningeal Tumors 2) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy 3) By Diagnosis Method: Imaging Techniques, Biopsy, Neurological Exam, Lumbar Puncture 4) By Age Group: Infants, Toddlers, Children, Adolescents 5) By Application: Hospitals And Clinics, Medical Research Centers, Academic Institutes, Other Applications Subsegments: 1) By Gliomas: Low-Grade Gliomas, High-Grade Gliomas 2) By Mixed Neuronal-Glial Tumors: Gangliogliomas, Dysembryoplastic Neuroepithelial Tumors (DNET) 3) By Embryonal Tumors: Medulloblastoma, Atypical Teratoid Rhabdoid Tumor (ATRT), Primitive Neuroectodermal Tumors (PNET) 4) By Choroid Plexus Papilloma Or Carcinoma: Choroid Plexus Papilloma, Choroid Plexus Carcinoma 5) By Tumors Arising From Non-Neuroepithelial Tissue: Rhabdomyosarcoma, Ewing's Sarcoma 6) By Meningeal Tumors: Meningiomas, Hemangiopericytomas

What Is The Driver Of The Pediatric Brain Tumors Market?

The growing demand for personalized medicine is expected to propel the growth of the pediatric brain tumors market going forward. Personalized medicine is a healthcare strategy that customizes treatments and medical decisions according to a person's genetic makeup, lifestyle, and unique health requirements. The demand for personalized medicine rises due to advancements in genetic research, improved diagnostic tools, and the potential for more effective and targeted treatments. Personalized medicine enables targeted therapies that are more effective and cause less damage to healthy tissue by tailoring treatments to the child's specific tumor type, mutation, and response, it enhances outcomes and reduces side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, growing demand for personalized medicine is driving the growth of the pediatric brain tumor industry.

Key Players In The Global Pediatric Brain Tumors Market

Major companies operating in the pediatric brain tumors market are Bayer AG, Novartis AG, Roche Holding AG, Takeda Pharmaceutical Company, UCLA Health, Novocure, Blueprint Medicines, Oncoheroes Biosciences, Plus Therapeutics Inc., Stemline Therapeutics Inc., BrainChild Bio Inc., Seattle Children's Therapeutics, Pfizer Inc., Merck & Co Inc., Bristol Myers Squibb Company, Sanofi, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Eli Lilly and Company, Day One Biopharmaceuticals Inc., Biodexa Pharmaceuticals, Cellectar Biosciences Inc., ZIOPHARM Oncology Inc., Y‑mAbs Therapeutics Inc., Neonc Technologies Inc.

Global Pediatric Brain Tumors Market Trends and Insights

Major companies operating in the pediatric brain tumors market are focusing on developing advanced treatments such as type II RAF inhibitors to enhance targeted therapies and improve patient outcomes. Type II RAF inhibitors are targeted therapies that focus on inhibiting RAF kinases, specifically those with mutations that drive tumor growth. These inhibitors are designed to target abnormal RAF protein structures found in certain pediatric low-grade glioma (pLGG) subtypes, effectively blocking the faulty signaling pathways that contribute to tumor cell proliferation and survival. For instance, in April 2024, Day One Biopharmaceuticals, a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for OJEMDA (tovorafenib) for the treatment of relapsed or refractory pediatric low-grade glioma (pLGG) in patients aged 6 months and older with specific BRAF alterations. This approval makes OJEMDA the first FDA-approved therapy targeting BRAF fusions or mutations in this patient population. The approval is based on the reported overall response rate of 51% from the FIREFLY-1 clinical trial, which assessed the drug's efficacy in this indication. It is specifically targeted towards children with brain tumor that has not responded to previous treatments.

What Are Latest Mergers And Acquisitions In The Pediatric Brain Tumors Market?

In July 2024, Ipsen, a France-based biopharmaceutical company, partnered with Day One Biopharmaceuticals to commercialize tovorafenib for pediatric low-grade glioma (pLGG) outside of the United States. Through this collaboration, Ipsen will oversee regulatory and commercial activities for tovorafenib on a global scale. Day One Biopharmaceuticals is a US-based provider of treatment for childhood brain tumors such as OJEMDA.

Regional Outlook

North America was the largest region in the pediatric brain tumors market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pediatric Brain Tumors Market?

The pediatric brain tumor market consists of revenues earned by entities providing services such as neuro-oncology care, rehabilitation services, psychosocial support, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The pediatric brain tumor market also includes sales of chemotherapy drugs, surgical instruments, and radiation therapy equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pediatric Brain Tumors Market Report 2026?

The pediatric brain tumors market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric brain tumors industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.